The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets

Transfusion

Volumn 54, Issue 9, 2014, Pages 2207-2216

  Castro, Emma ^a   González, Luis Miguel ^b   Rubio, Jose Miguel ^b   Ramiro, Raquel ^b   Gironés, Núria ^c   Montero, Estrella ^b  

^a Centro de Transfusión de Cruz Roja Española en Madrid   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BABESIA DIVERGENS; BLOOD BANK; BLOOD COMPONENT; BUFFY COAT DERIVED PLATELET; CONTROLLED STUDY; DNA SYNTHESIS; ERYTHROCYTE; IN VITRO STUDY; INFECTED RED BLOOD CELL; LIMIT OF DETECTION; NONHUMAN; PARASITE DEVELOPMENT; PARASITE INACTIVATION; PARASITE PHENOMENA AND FUNCTIONS; PARASITE VIABILITY; PARASITEMIA; PATHOGEN REDUCTION SYSTEM; SENSITIVITY ANALYSIS; THERAFLEX ULTRAVIOLET C PLATELET SYSTEM; THROMBOCYTE; ULTRAVIOLET C RADIATION; BABESIA; BLOOD BUFFY COAT; CYTOLOGY; HUMAN; PARASITOLOGY; PATHOGENICITY; RADIATION RESPONSE; ULTRAVIOLET RADIATION;

BABESIA; BLOOD BUFFY COAT; BLOOD PLATELETS; HUMANS; ULTRAVIOLET RAYS;

EID: 84908222411     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12598     Document Type: Article

References (34)

1. Fitzpatrick JE, Kennedy CC, McGeown MG, et al. Human case of piroplasmosis (babesiosis). Nature 1968;217:861-2.
2. Esernio-Jenssen D, Scimeca PG, Benach JL, et al. Transplacental/perinatal babesiosis. J Pediatr 1987;110: 570-2.
3. New DL, Quinn JB, Qureshi MZ, et al. Vertically transmitted babesiosis. J Pediatr 1997;131:163-4.
4. Sethi S, Alcid D, Kesarwala H, et al. Probable congenital babesiosis in infant, New Jersey, USA. Emerg Infect Dis 2009;15:788-91.
5. Herwaldt BL, Linden JV, Bosserman E, et al. Transfusionassociated babesiosis in the United States: a description of cases. Ann Intern Med 2011;155:509-19.
6. Johnson ST, Cable RG, Leiby DA. Lookback investigations of Babesia microti-seropositive blood donors: seven-year experience in a Babesia-endemic area. Transfusion 2012; 52:1509-16.
7. Lobo CA, Rodriguez M, Cursino-Santos JR. Babesia and red cell invasion. Curr Opin Hematol 2012;19:170-5.
8. Hunfeld KP, Hildebrandt A, Gray JS. Babesiosis: recent insights into an ancient disease. Int J Parasitol 2008;38: 1219-37.
9. Krause PJ, Spielman A, Telford SR III, et al. Persistent parasitemia after acute babesiosis. N Engl J Med 1998;339: 160-5.
10. Leiby DA. Transfusion-transmitted Babesia spp.: bull'seye on Babesia microti. Clin Microbiol Rev 2011;24:14-28.
11. Bloch EM, Herwaldt BL, Leiby DA, et al. The third described case of transfusion-transmitted Babesia duncani. Transfusion 2012;52:1517-22.
12. Herwaldt BL, Kjemtrup AM, Conrad PA, et al. Transfusiontransmitted babesiosis inWashington State: first reported case caused by aWA1-type parasite. J Infect Dis 1997;175: 1259-62.
13. Gubernot DM, Lucey CT, Lee KC, et al. Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007. Clin Infect Dis 2009;48:25-30.
14. Menis M, Anderson SA, Izurieta HS, et al. Babesiosis among elderly Medicare beneficiaries, United States, 2006-2008. Emerg Infect Dis 2012;18:128-31.
15. Vannier E, Krause PJ. Human babesiosis. N Engl J Med 2012;366:2397-407.
16. Hildebrandt A, Hunfeld KP, Baier M, et al. First confirmed autochthonous case of human Babesia microti infection in Europe. Eur J Clin Microbiol Infect Dis 2007;26:595-601.
17. Garnham PC. Human babesiosis: European aspects. Trans R Soc Trop Med Hyg 1980;74:153-5.
18. Grellier P, Benach J, Labaied M, et al. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 2008;48:1676-84.
19. Tonnetti L, Proctor MC, Reddy HL, et al. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010;50:1019-27.
20. Seghatchian J, Tolksdorf F. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system-an update. Transfus Apher Sci 2012;46: 221-9.
21. Seltsam A, Muller TH. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011;38:43-54.
22. Castro E, Girones N, Guerrero NA, et al. The effectiveness of UVC pathogen inactivation system on reducing the Trypanosoma Cruzi and Leishmania Infantum burden in platelets. Vox Sang 2008;95(Suppl 1):74-326.
23. Murphy S. Platelets from pooled buffy coats: an update. Transfusion 2005;45:634-9.
24. Montero E, Gonzalez LM, Rodriguez M, et al. A conserved subtilisin protease identified in Babesia divergens merozoites. J Biol Chem 2006;281:35717-26.
25. Castro E, Girones N, Bueno JL, et al. The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets. Transfusion 2007;47:434-41.
26. Risso MG, Garbarino GB, Mocetti E, et al. Differential expression of a virulence factor, the trans-sialidase, by the main Trypanosoma cruzi phylogenetic lineages. J Infect Dis 2004;189:2250-9.
27. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and longwavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004;44:1496-504.
28. Martinot M, Zadeh MM, Hansmann Y, et al. Babesiosis in immunocompetent patients, Europe. Emerg Infect Dis 2011;17:114-6.
29. Centeno-Lima S, do Rosário V, Parreira R, et al. A fatal case of human babesiosis in Portugal: molecular and phylogenetic analysis. Trop Med Int Health 2003;8:760-4.
30. Gray JS, Gannon P. Preliminary development of a live drug-controlled vaccine against bovine babesiosis using the Mongolian gerbil, Meriones unguiculatus. Vet Parasitol 1992;42:179-88.
31. Lewis D, Young ER, Baggott DG, et al. Babesia divergens infection of the Mongolian gerbil: titration of infective dose and preliminary observations on the disease produced. J Comp Pathol 1981;91:565-72.
32. Hildebrandt A, Gray JS, Hunfeld KP. Human babesiosis in Europe: what clinicians need to know. Infection 2013;41: 1057-72.
33. Schrezenmeier H, Seifried E. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010; 99:1-15.
34. Lozano M, Cid J, Areal C, et al. Apheresis activity in Spain: a survey of the Spanish Apheresis Group. Transfus Apher Sci 2013;49:560-4.